Palonosetron, a highly effective 5-HT3 antagonist, has revolutionized the treatment of chemotherapy-induced nausea and vomiting (CINV). As a leading player in the pharmaceutical industry, expanding your reach to global buyers is crucial for maximizing market share and driving sales growth. This article provides a valuable resource for Palonosetron manufacturers and suppliers, offering a comprehensive overview of the global buyer landscape. Key Market Segments: Hospitals and Clinics: The primary users of Palonosetron are hospitals and clinics specializing in oncology and cancer treatment. Understanding the purchasing decisions and procurement processes within these institutions is vital. Group Purchasing Organizations (GPOs): GPOs negotiate bulk discounts on behalf of hospitals and clinics, making them a…